Home
Luye Pharma

Luye Pharma Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainluye.cn

Year Founded1994

Employees1001 - 5000

Annual Revenue$500M - $1B

Luye Pharma

Luye Pharma (including company regionals)

luye.cn

See more website traffic and engagement information

Luye Pharma Revenue up to May 2026 is 500M - 1B

revenue generated by Luye Pharma top domains

Luye Pharma top domains revenue over 3 years

Revenue for Luye Pharma top domains

luye.cn500M - 1B

See more with Sales Intelligence

Luye Pharma Stock price in May 2026

Luye Pharma stock is traded under the ticker #02186. Below you can review Luye Pharma stock performance in the past 12 months up to May 2026

Total visits to Luye Pharma's top domains

Understand Luye Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

luye.cn5.6K

See more with Sales Intelligence

Avg. visit duration in Luye Pharma's top domains

Analyze Luye Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

luye.cn00:00:26

See more with Sales Intelligence

Avg. pageviews on Luye Pharma's top domains

See how Luye Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

luye.cn1.84

See more with Sales Intelligence

Luye Pharma top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Luye Pharma

These are the website technologies, by industry, used by Luye Pharma top domains

Conversion & Analytics (2)

CNZZ

Advertising (1)

PubMatic

Email Services (1)

Microsoft Exchange Online

Mobile (1)

Meta Viewport

More Technologies

2

See all

News & Signals from Luye Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsLuye Pharma Group launches Zepzelca drug in Hong Kong and Macao for treatment of Small Cell Lung Cancer.Luye Pharma launches Zepzelca drug in Hong Kong and Macao for treatment of Small Cell Lung Cancer.

NewsLuye Pharma Group launches drug Zepzelca.At the conference, Luye Pharma announced the launch of its innovative drug Zepzelca(R) (lurbinectedin) for the treatment of SCLC in both Hong Kong and Macao, the two Special Administrative Regions of China.

NewsLuye Pharma Group launched Rivastigmine Transdermal Patch in China on Jan 1st '21.In January 2021, Luye Pharma Group held a press conference to announce the launch of its Rivastigmine Transdermal Patch in China.